专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

KR101495685B1 ＬＯＣ２８４４２２ 유전자의 신규한 용도 有权
标题翻译：新型使用LOC284422基因
公开(公告)号：KR101495685B1
公开(公告)日：2015-02-26
申请号：KR1020080124481
申请日：2008-12-09
申请人： 한국생명공학연구원
发明人： 원미선 , 정경숙 , 조선정 , 최신정 , 염영일 , 김선영 , 송경빈 , 이희구 , 송은영 , 김영호 , 전호경 , 김문희 , 정경은 , 오유경
IPC分类号： C12N15/12 , C12N15/10 , C12Q1/68 , G01N33/574
CPC分类号： C07K14/4748 , C12N15/113 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , G01N33/57484 , G01N2500/00
摘要： 본 발명은 LOC284422 유전자 또는 LOC284422 유전자로부터 발현된 단백질에 대한 항체를 포함하는 암 진단용 또는 항암제 스크리닝용 조성물, 상기 유전자의 억제제 또는 상기 유전자로부터 발현된 단백질의 억제제 및 약제학적으로 허용되는 담체를 포함하는 암 치료용 조성물, LOC284422 유전자 또는 LOC284422 유전자로부터 발현된 단백질 중 하나 이상을 포함하는 암 진단용 키트를 제공한다. 본 발명의 LOC284422 유전자는 암 세포에 다량 발현되고 정상세포의 증식 속도를 증가시키므로, 이들 유전자의 발현을 저해시키면 암세포의 성장을 억제시키는 작용 효과를 가져온다. 따라서 LOC284422 유전자는 각종 암의 진단 또는 치료제의 표적 유전자로 활용될 수 있다.
LOC284422, 암, siRNA

22. 发明授权

KR101466661B1 ＴＭＣ５ 유전자의 신규한 용도 有权
标题翻译：新型使用TMC5基因
公开(公告)号：KR101466661B1
公开(公告)日：2014-12-01
申请号：KR1020080013546
申请日：2008-02-14
申请人： 한국생명공학연구원
发明人： 원미선 , 정경숙 , 김영주 , 최신정 , 정유진 , 염영일 , 김선영 , 송경빈 , 이희구 , 송은영 , 김영호 , 전호경 , 김문희 , 정경은
IPC分类号： C07K14/47 , C12N15/12 , C12Q1/68
摘要： 본발명은 TMC5 유전자또는 TMC5 유전자로부터발현된단백질에대한항체를포함하는암 진단용또는항암제스크리닝용조성물, 상기유전자의억제제또는상기유전자로부터발현된단백질의억제제및 약제학적으로허용되는담체를포함하는암 치료용조성물, TMC5 유전자또는 TMC5 유전자로부터발현된단백질중 하나이상을포함하는암 진단용키트를제공한다. 본발명의 TMC5 유전자는암 세포에다량발현되고정상세포의증식속도를증가시키므로, 이들유전자의발현을저해시키면암세포의성장을억제시키는작용효과를가져온다. 따라서 TMC5 유전자는각종암의진단또는치료제의표적유전자로활용될수 있다.

23. 发明公开

KR1020100065898A ＬＯＣ２８４４２２ 유전자의 신규한 용도 有权
标题翻译： LOC284422基因的新用途
公开(公告)号：KR1020100065898A
公开(公告)日：2010-06-17
申请号：KR1020080124481
申请日：2008-12-09
申请人： 한국생명공학연구원
发明人： 원미선 , 정경숙 , 조선정 , 최신정 , 염영일 , 김선영 , 송경빈 , 이희구 , 송은영 , 김영호 , 전호경 , 김문희 , 정경은 , 오유경
IPC分类号： C12N15/12 , C12N15/10 , C12Q1/68 , G01N33/574
CPC分类号： C07K14/4748 , C12N15/113 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , G01N33/57484 , G01N2500/00 , C12Q2600/178 , G01N33/15
摘要： PURPOSE: A LOC284422 gene is provided to overexpress in cancer cells, to increase proliferation rate of normal cells and to treat or diagnose various cancers. CONSTITUTION: A composition for diagnosing cancer contains LOC284422 gene. The composition contains an antibody to a protein expressed from the LOC284422 gene. A composition for screening an anticancer drug contains LOC284422 gene and a protein expressed from the LOC284422 gene. A composition for treating cancer contains an inhibitor to LOC284422 gene. The inhibitor is an antisense oligonucleotide to LOC284422 mRNA.
摘要翻译：目的：提供LOC284422基因在癌细胞中过表达，以增加正常细胞的增殖率和治疗或诊断各种癌症。构成：用于诊断癌症的组合物含有LOC284422基因。该组合物含有由LOC284422基因表达的蛋白质的抗体。用于筛选抗癌药物的组合物含有LOC284422基因和由LOC284422基因表达的蛋白质。用于治疗癌症的组合物含有LOC284422基因的抑制剂。抑制剂是LOC284422 mRNA的反义寡核苷酸。

24. 发明公开

KR1020100054009A 리포터 시스템을 이용한 메틸트렌스퍼레이즈 저해 물질 스크리닝 방법 有权
标题翻译：使用报告系统筛选试剂抑制甲基转移酶的方法
公开(公告)号：KR1020100054009A
公开(公告)日：2010-05-24
申请号：KR1020080112923
申请日：2008-11-13
申请人： 한국생명공학연구원
发明人： 원미선 , 이경 , 이정준 , 정경숙 , 박성규 , 권병목 , 임남희 , 강정은 , 김영란 , 하연 , 송경빈 , 최용석
IPC分类号： C12N15/12 , C12N15/09 , C12N15/64
摘要： PURPOSE: A vector comprising VHL(von Hippel-Lindau) promoter and Drosophila luciferase gene as a reporter gene and a method for screening DNA methyltansferase inhibitor using the same are provided to screen a therapeutic agent for neural disorder, blood disease, or tumor. CONSTITUTION: A recombinant expression vector comprises a VHL(von Hippel-Lindau) promoter of sequence number 1, 2, 3, 4, or 5, and fluorescence protein gene which is fused to the promoter. The fluorescence protein is Drosophila luciferase, enhsnce green fluorescent protein(EGFP), or cyan fluorescent protein(CFP). The VHL promoter is a promoter of sequence number 5. The fluorescence protein is Drosophila luciferase. A transformed cell line is obtained by transforming a pRL-SV40 plasmid vector containing the recombinant expression vector and renila-luciferase. A method for screening a DNA methyltransferase inhibitor comprises: a step of culturing transformed cell line in a plate; a step of adding a sample to detect and culturing in hypoxia condition; and a step of measuring fluorescence and renila-luciferase fluorescence.
摘要翻译：目的：提供包含VHL（von Hippel-Lindau）启动子和果蝇萤光素酶基因作为报告基因的载体和筛选用于神经障碍，血液病或肿瘤的治疗剂的筛选DNA甲基转移酶抑制剂的方法。构成：重组表达载体包含序列号1,2,3,4或5的VHL（von Hippel-Lindau）启动子和与启动子融合的荧光蛋白基因。荧光蛋白是果蝇萤光素酶，绿色荧光蛋白（EGFP）或青色荧光蛋白（CFP）。 VHL启动子是序列号5的启动子。荧光蛋白是果蝇萤光素酶。通过转化含有重组表达载体和肾素 - 荧光素酶的pRL-SV40质粒载体获得转化的细胞系。筛选DNA甲基转移酶抑制剂的方法包括：在板中培养转化细胞系的步骤; 在缺氧条件下添加样品进行检测和培养的步骤; 以及测量荧光和肾素 - 荧光素酶荧光的步骤。

25. 发明公开

KR1020090060183A ＦＬＪ２５４１６ 유전자의 신규한 용도 有权
标题翻译： FLJ25416基因的新用途
公开(公告)号：KR1020090060183A
公开(公告)日：2009-06-11
申请号：KR1020080122892
申请日：2008-12-05
申请人： 한국생명공학연구원 , 에스티팜 주식회사
发明人： 원미선 , 정경숙 , 김영주 , 최신정 , 염영일 , 김선영 , 송경빈 , 이희구 , 송은영 , 김영호 , 전호경 , 윤채옥 , 김문희 , 정경은 , 조선정
IPC分类号： C12N15/12 , C12Q1/68 , C12Q1/00 , G01N33/574
CPC分类号： G01N33/57484 , A61K31/7088 , A61K38/1709 , C12N15/1135 , C12N15/86 , C12N2310/111 , C12N2310/14 , C12N2710/10343 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N2500/00 , G01N2500/04 , C12Q2600/178 , G01N33/15 , G01N33/6857
摘要： A use of FLJ25416 gene as a target gene of anti-cancer drug or therapeutic agent is provided. A composition for diagnosing cancer comprises a FLJ25416 gene or antibody to a protein which is expressed from the FLJ25416 gene. A composition for screening an anticancer drug comprises the FLJ25416 gene or the protein which is expressed from the gene. A composition for treating cancer comprises an inhibitor to the FLJ25416 gene and an inhibitor to the protein which is expressed by the FLJ25416 gene. The inhibitor of FLJ25416 gene is anti-sense oligonucleotide to FLJ25416 mRNA. Or, the inhibitor to the FLJ25416 gene is siRNA or shRNA of FLJ25416 gene.
摘要翻译：提供了使用FLJ25416基因作为抗癌药物或治疗剂的靶基因。用于诊断癌症的组合物包含FLJ25416基因或由FLJ25416基因表达的蛋白质的抗体。用于筛选抗癌药物的组合物包含FLJ25416基因或从该基因表达的蛋白质。用于治疗癌症的组合物包含FLJ25416基因的抑制剂和由FLJ25416基因表达的蛋白质的抑制剂。 FLJ25416基因的抑制剂是FLJ25416 mRNA的反义寡核苷酸。或者，FLJ25416基因的抑制剂是FLJ25416基因的siRNA或shRNA。

26. 发明公开

KR1020090054596A 분열효모용 발현벡터, 그 제조방법 및 분열효모 배양용배지 조성물 无效
标题翻译：用于展示YEAST的表达载体，其构造方法和用于培养年龄的中等组成
公开(公告)号：KR1020090054596A
公开(公告)日：2009-06-01
申请号：KR1020070121341
申请日：2007-11-27
申请人： 한국생명공학연구원
发明人： 정경숙 , 원미선 , 안지원 , 최신정 , 임금옥 , 이희구 , 염영일 , 유향숙 , 송경빈 , 강창모
IPC分类号： C12N15/64 , C12N15/81 , C12N15/09
摘要： An expression vector for fission yeast containing a nourseothricin resistance gene is provided to screen the fission yeast in minimal medium. An expression vector for fission yeast comprises a nourseothricin resistance gene as a marker gene. A method for manufacturing the expression vector for fission yeast comprises: a step of removing open reading frame of geneticin resistance gene from a vector containing geneticin resistance gene cassette; a step of cloning the open reading frame of nourseothricin resistance gene to produce the vector containing nourseothricin resistance gene cassette; and a step of amplifying the nourseothricin resistance gene cassette through PCR.
摘要翻译：提供了含有鼻炎抗性基因的裂殖酵母的表达载体，以筛选基本培养基中的裂殖酵母。裂殖酵母的表达载体包含作为标记基因的鼻炎抗性基因。制备裂殖酵母表达载体的方法包括：从含有遗传霉素抗性基因盒的载体中除去遗传霉素抗性基因的开放阅读框的步骤; 克隆含有鼻炎抗性基因的开放阅读框的步骤来产生含有鼻炎抗性基因盒的载体; 以及通过PCR扩增鼻息肉抗性基因盒的步骤。

27. 发明公开

KR1020090054595A 분열효모용 발현벡터, 그 제조방법 및 분열효모 배양용배지 조성물 有权
标题翻译：用于展示YEAST的表达载体，其构造方法和用于培养年龄的中等组成
公开(公告)号：KR1020090054595A
公开(公告)日：2009-06-01
申请号：KR1020070121340
申请日：2007-11-27
申请人： 한국생명공학연구원
发明人： 정경숙 , 원미선 , 최정해 , 박수현 , 임남희 , 송은영 , 염영일 , 유향숙 , 송경빈 , 강창모
IPC分类号： C12N15/64 , C12N15/81 , C12N15/09
摘要： An expression vector for fission yeast is provided to screen the fission yeast having antibiotics resistance gene and keep the activation of the antibiotics in minimal medium. An expression vector for fission yeast comprises a hygromycin resistance gene as a marker gene. The hygromycin resistance gene has a sequence of the sequence number 3. A method for manufacturing the expression vector for fission yeast comprises: a step of removing an open reading frame of geneticin resistance gene from a vector; a step of cloning the open reading frame of geneticin resistance gene into the vector to produce a vector containing hygromycin resistance gene cassette; and a step of amplifying the hygromycin resistance gene cassette through PCR to clone the expression vector for fission yeast whose marker is removed.
摘要翻译：提供裂殖酵母的表达载体，筛选具有抗生素抗性基因的裂殖酵母，并在基本培养基中保持抗生素的活化。裂殖酵母的表达载体包含潮霉素抗性基因作为标记基因。潮霉素抗性基因具有序列号3的序列。裂殖酵母表达载体的制造方法包括：从载体中除去遗传霉素抗性基因的开放阅读框的步骤; 将遗传霉素抗性基因的开放阅读框克隆到载体中以产生含有潮霉素抗性基因盒的载体的步骤; 以及通过PCR扩增潮霉素抗性基因盒以克隆除去标记物的裂殖酵母表达载体的步骤。

28. 发明公开

KR1020090021542A ＤＤＸ41 및 ＡＳＣＣ2 유전자의 신규한 용도 无效
标题翻译： DDX41和ASCC2基因的新用途
公开(公告)号：KR1020090021542A
公开(公告)日：2009-03-04
申请号：KR1020070086134
申请日：2007-08-27
申请人： 한국생명공학연구원
发明人： 원미선 , 정경숙 , 김영주 , 최신정 , 김동명 , 유향숙 , 송경빈 , 임남희
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/178 , G01N33/6857
摘要： Provided is a composition for cancer diagnosis including antibodies to a DDX41 gene and an ASCC2 gene as target genes which are expressed to a cancer cell and increase a multiplication rate of normal cells. A composition for cancer diagnosis comprises antibodies to a DDX41 gene and an expressed protein from a DDX41 gene. A composition for an anti-cancer medicine screening consists of a DDX41 gene and an expressed protein from the DDX41 gene. A composition for cancer treatment includes an inhibitor against the DDX41 gene and a carrier which is pharmaceutical allowed to be used. The inhibitor against the DDX41 gene is siRNA of the DDX41 gene.
摘要翻译：本发明提供一种用于癌症诊断的组合物，其包括DDX41基因和ASCC2基因的抗体作为靶向基因，其被表达于癌细胞并增加正常细胞的增殖率。用于癌症诊断的组合物包括DDX41基因的抗体和来自DDX41基因的表达的蛋白质。用于抗癌药物筛选的组合物由DDX41基因和来自DDX41基因的表达蛋白质组成。用于癌症治疗的组合物包括针对DDX41基因的抑制剂和允许使用药物的载体。 DDX41基因的抑制剂是DDX41基因的siRNA。

29. 发明公开

KR1020080053223A ＯＩＰ５ 유전자의 신규한 용도 失效
标题翻译： OIP5基因的新用途
公开(公告)号：KR1020080053223A
公开(公告)日：2008-06-12
申请号：KR1020070126815
申请日：2007-12-07
申请人： 한국생명공학연구원 , 주식회사 삼천리제약
发明人： 원미선 , 정경숙 , 김영주 , 최신정 , 김동명 , 임남희 , 안지원 , 허철구 , 송경빈 , 김문희 , 정경은 , 이형주 , 염영일 , 이희구 , 송은영
IPC分类号： C12Q1/68 , G01N33/574 , C07K14/39 , C12Q1/00
CPC分类号： C12Q1/6886 , C12Q2600/136 , G01N33/15 , G01N33/574 , G01N2033/57461 , G01N2033/57465
摘要： An OIP gene is provided to diagnose cancer by detecting overexpression of gene or protein in cells by using the expression increase properties in cancer cells, screen anticancer agent by measuring increase or decrease of gene expression by a candidate anticancer material and treat cancer by using OIP gene inhibitors. A composition for screening anticancer agent comprises an OIP gene or a protein expressed from the OIP gene. A screening method of anticancer agent comprises the steps of: contacting the anticancer agent-screening composition as a target material with a candidate anticancer material; analyzing the reaction between the target material and the candidate anticancer material; and deciding the activity of candidate anticancer material to increase or inhibit the gene expression. The siRNA(small interfering RNA) of OIP gene comprises the nucleotide sequence corresponding to mRNA derived from 19-30 consecutive nucleotide sequences in at least on sequence selected from SEQ ID NOs:19, 20, 21, 22, 23, 24, 25 and 26, and has the nucleotide sequence of SEQ ID NO:3 or 4. The shRNA(short hairpin RNA) of OIP gene comprises the nucleotide sequence corresponding to mRNA derived from 19-30 consecutive nucleotide sequences in at least on sequence selected from SEQ ID NOs:19, 20, 21, 22, 23, 24, 25 and 26, and has RNA sequence of SEQ ID NO:5 and reversely complementary RNA sequence connected thereto with 3-10 base of loop area. A composition for treating cancer contains siRNA of OIP gene or shRNA of OIP gene as OIP gene inhibitor.
摘要翻译：通过使用癌细胞中的表达增加性质，筛选抗癌剂，通过测定候选抗癌物质的基因表达的增加或减少并通过使用OIP基因治疗癌症来提供OIP基因来检测细胞中基因或蛋白质的过表达抑制剂。用于筛选抗癌剂的组合物包含OIP基因或由OIP基因表达的蛋白质。抗癌剂的筛选方法包括以下步骤：将抗癌剂筛选组合物作为靶材料与候选抗癌材料接触; 分析目标材料与候选抗癌材料之间的反应; 并决定候选抗癌物质的活性以增加或抑制基因表达。 OIP基因的siRNA（小干扰RNA）包含对应于至少在选自SEQ ID NO：19,20,21,22,23,24,25的序列上源自19-30个连续核苷酸序列的mRNA的核苷酸序列，以及 26，并且具有SEQ ID NO：3或4的核苷酸序列.OIP基因的shRNA（短发夹RNA）包含对应于源自19-30个连续核苷酸序列的mRNA的核苷酸序列，至少在选自SEQ ID NO： NO：19,20,21,22,23,24,25和26，并且具有SEQ ID NO：5的RNA序列和与3-10个环面积连接的反向互补RNA序列。用于治疗癌症的组合物含有OIP基因的siRNA或OIP基因的shRNA作为OIP基因抑制剂。

30. 发明公开

KR1020080053222A ＭＩＧ１２ 유전자의 신규한 용도 失效
标题翻译： MIG12基因的新用途
公开(公告)号：KR1020080053222A
公开(公告)日：2008-06-12
申请号：KR1020070126814
申请日：2007-12-07
申请人： 한국생명공학연구원 , 주식회사 삼천리제약
发明人： 원미선 , 정경숙 , 김영주 , 최신정 , 김동명 , 임남희 , 안지원 , 허철구 , 송경빈 , 김문희 , 정경은 , 이형주 , 염영일 , 이희구 , 송은영
IPC分类号： C12Q1/68 , G01N33/574 , C07K14/39 , C12Q1/00
CPC分类号： C12Q1/6886 , C12Q2600/136 , G01N33/15 , G01N33/574 , G01N2033/57461 , G01N2033/57465
摘要： A MIG12 gene is provided to increase its expression in cancer cells and promote growth rate of normal cells, so that the gene is useful for diagnosis of cancer and useful as a target gene of cancer therapeutic agent. A composition for diagnosis of cancer comprises a MIG12 gene, a protein encoded by the MIG12 gene or an antibody against the MIG12 protein. A composition for screening of anticancer agent comprises the MIG12 gene or a protein encoded by the MIG12 gene. A composition for treatment of cancer comprises an inhibitor of MIG12 gene selected from siRNA(small interfering RNA) and shRNA(short hairpin RNA) of MIG12, wherein the siRNA of MIG12 has the nucleotide sequence of SEQ ID NO:3 or 4; and the shRNA of MIG12 comprises RNA sequence of SEQ ID NO:4 and reversely complementary RNA sequence connected thereto with the 3-10 base of loop area.
摘要翻译：提供MIG12基因以增加其在癌细胞中的表达并促进正常细胞的生长，使得该基因可用于诊断癌症并且可用作癌症治疗剂的靶基因。用于诊断癌症的组合物包含MIG12基因，由MIG12基因编码的蛋白或针对MIG12蛋白的抗体。用于筛选抗癌剂的组合物包含MIG12基因或由MIG12基因编码的蛋白质。用于治疗癌症的组合物包含选自MIG12的siRNA（小干扰RNA）和shRNA（短发夹RNA）的MIG12基因的抑制剂，其中MIG12的siRNA具有SEQ ID NO：3或4的核苷酸序列; 并且MIG12的shRNA包含SEQ ID NO：4的RNA序列和与其连接的反向互补RNA序列与3-10碱基的环面积。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式